- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Bone Marrow Research
Volume 2011 (2011), Article ID 524845, 8 pages
Factors Influencing the Abundance of the Side Population in a Human Myeloma Cell Line
1The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
2Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
3Institute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia
4Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW 2006, Australia
5Faculty of Medicine, The University of New South Wales, Sydney, NSW 2052, Australia
6Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong
Received 21 March 2011; Accepted 26 July 2011
Academic Editor: Ignazio Majolino
Copyright © 2011 Sui-Lin Mo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. A. Goodell, K. Brose, G. Paradis, A. S. Conner, and R. C. Mulligan, “Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo,” Journal of Experimental Medicine, vol. 183, no. 4, pp. 1797–1806, 1996.
- M. A. Goodell, M. Rosenzweig, H. Kim et al., “Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species,” Nature Medicine, vol. 3, no. 12, pp. 1337–1345, 1997.
- L. Moserle, S. Indraccolo, M. Ghisi et al., “The side population of ovarian cancer cells is a primary target of IFN-α antitumor effects,” Cancer Research, vol. 68, no. 14, pp. 5658–5668, 2008.
- T. Kondo, T. Setoguchi, and T. Taga, “Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 781–786, 2004.
- M. M. Ho, A. V. Ng, S. Lam, and J. Y. Hung, “Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells,” Cancer Research, vol. 67, no. 10, pp. 4827–4833, 2007.
- J. Wang, L. P. Guo, L. Z. Chen, Y. X. Zeng, and H. L. Shih, “Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line,” Cancer Research, vol. 67, no. 8, pp. 3716–3724, 2007.
- N. Haraguchi, T. Utsunomiya, H. Inoue et al., “Characterization of a side population of cancer cells from human gastrointestinal system,” Stem Cells, vol. 24, no. 3, pp. 506–513, 2006.
- T. Chiba, S. Miyagi, A. Saraya et al., “The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma,” Cancer Research, vol. 68, no. 19, pp. 7742–7749, 2008.
- C. Wu, Q. Wei, V. Utomo et al., “Side population cells isolated from mesenchymal neoplasms have tumor initiating potential,” Cancer Research, vol. 67, no. 17, pp. 8216–8222, 2007.
- Y. S. Loh, S. Mo, R. D. Brown et al., “Presence of Hoechst low side populations in multiple myeloma,” Leukemia and Lymphoma, vol. 49, no. 9, pp. 1813–1816, 2008.
- L. Q. Yin, P. Castagnino, and R. K. Assoian, “ABCG2 expression and side population abundance regulated by a transforming growth factor β-directed epithelial-mesenchymal transition,” Cancer Research, vol. 68, no. 3, pp. 800–807, 2008.
- I. Sales-Pardo, A. Avendaño, V. Martinez-Muñoz et al., “Flow cytometry of the side population: tips and tricks,” Cellular Oncology, vol. 28, no. 1-2, pp. 37–53, 2006.
- Y. Morita, H. Ema, S. Yamazaki, and H. Nakauch, “Non-side-population hematopoietic stem cells in mouse bone marrow,” Blood, vol. 108, no. 8, pp. 2850–2856, 2006.
- F. Montanaro, K. Liadaki, J. Schienda, A. Flint, E. Gussoni, and L. M. Kunkel, “Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters,” Experimental Cell Research, vol. 298, no. 1, pp. 144–154, 2004.
- S. F. Ibrahim, A. H. Diercks, T. W. Petersen, and G. van den Engh, “Kinetic analyses as a critical parameter in defining the side population (SP) phenotype,” Experimental Cell Research, vol. 313, no. 9, pp. 1921–1926, 2007.
- E. Boye and K. Nordström, “Coupling the cell cycle to cell growth. A look at the parameters that regulate cell-cycle events,” EMBO Reports, vol. 4, no. 8, pp. 757–760, 2003.
- M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005.
- M. Kim, H. Turnquist, J. Jackson et al., “The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells,” Clinical Cancer Research, vol. 8, no. 1, pp. 22–28, 2002.
- J. W. Jonker, J. Freeman, E. Bolscher et al., “Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice,” Stem Cells, vol. 23, no. 8, pp. 1059–1065, 2005.
- P. P. Szotek, R. Pieretti-Vanmarcke, P. T. Masiakos et al., “Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 30, pp. 11154–11159, 2006.
- C. Schmidt, “Drug makers chase cancer stem cells,” Nature Biotechnology, vol. 26, no. 4, pp. 366–367, 2008.